NanoString's Assets to be Acquired by Bruker

In a year that’s already filled with M&A, Bruker said it will acquire NanoString for $392 million.

Omar Ford

April 23, 2024

1 Min Read
Image Credit: Maks Lab via iStock/Getty Images

A little more than two months ago, NanoString Technologies filed for bankruptcy – weary from having to pay $31 million to 10X Genomics after losing a patent infringement lawsuit.

Today is a different story as the Seattle, WA-based company’s assets have received a lifeline through M&A. Recently Bruker Corporation said it would acquire NanoString Technologies for about $392 million.

NanoString is a provider of solutions for spatial transcriptomics and gene expression analysis.

Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString’s business, including the nCounter, GeoMx, CosMx , and AtoMx product lines.

“The acquisition of NanoString will add gene expression profiling and spatial transcriptomics solutions and products to Bruker’s spatial biology portfolio,” said Mark R. Munch, President of the Bruker NANO Group. “NanoString’s innovative platforms are complementary to Bruker’s high-performance CellScape™ spatial proteomics platform. Over time we expect considerable, high-margin consumables pull-through, which is inherent in spatial and single-cell biology solutions.”

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like